Singapore Billionaire Kwek Family's City Developments Fails To Buy Out M&C New Zealand
City Developments—controlled by billionaire Kwek Leng Beng and his family—failed in its NZ$71 million ($42 million) bid to buy out Millennium & Copthorne Hotels New Zealand's minority shareholders.
The Singapore-listed property developer held almost 84% of M&C New Zealand at the close of the offer on Thursday, missing the 90% threshold it needed to delist the hotel company, M&C New Zealand said in a regulatory filing.
City Developments had originally offered in January to buy the remaining 24% of the hotel operator for NZ$2.25 a piece but the offer was raised to NZ$2.80 last month as independent directors deemed the first offer as too low.
Despite the improved offer, the independent directors urged minority shareholders to reject the offer, which is still below the fair value of at least NZ$4.40 apiece that was assessed by an independent adviser.
'The offer undervalues the benefits which can be expected as the tourism and property markets recover,' Leslie Preston, chair of the independent directors committee, has said in a letter to shareholders.
The failure to delist M&C New Zealand is another setback for City Developments, which is still reeling from a family feud that has dragged the company's shares to near historic lows and raised doubts whether the company can revive profits the were hurt by rising borrowing costs and slowing residential sales.
A dispute between City Developments CEO Sherman Kwek and his father, Kwek Leng Beng (who is City Developments' executive chairman) became public in late February after Leng Beng sued Sherman for control of the Singapore-listed property developer.
While the case has been withdrawn and both parties agreed to set aside their differences, the feud had cast the limelight on one of Singapore's wealthiest families with an estimated net worth of $11.5 billion. The rift had also cast a shadow at the company's shareholders' meeting last month.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
New Zealand Spending Slowdown Adds to Signs of Cooling Economy
New Zealand retail card spending fell in the second quarter, adding to signs that an initial spurt of economic growth early this year has all but disappeared. Purchases on debit and credit cards at retail stores fell 0.7% from the first quarter, when it was unchanged, Statistics New Zealand said Monday in Wellington. The value of spending is lower than in the year-earlier quarter when the economy was entering a deep depression.
Yahoo
a day ago
- Yahoo
Even after rising 6.8% this past week, Ryman Healthcare (NZSE:RYM) shareholders are still down 77% over the past five years
Ryman Healthcare Limited (NZSE:RYM) shareholders should be happy to see the share price up 14% in the last month. But will that heal all the wounds inflicted over 5 years of declines? Unlikely. Indeed, the share price is down a whopping 81% in that time. So we don't gain too much confidence from the recent recovery. The fundamental business performance will ultimately determine if the turnaround can be sustained. While a drop like that is definitely a body blow, money isn't as important as health and happiness. Although the past week has been more reassuring for shareholders, they're still in the red over the last five years, so let's see if the underlying business has been responsible for the decline. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Ryman Healthcare wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually desire strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit. In the last half decade, Ryman Healthcare saw its revenue increase by 13% per year. That's a fairly respectable growth rate. So the stock price fall of 13% per year seems pretty steep. The truth is that the growth might be below expectations, and investors are probably worried about the continual losses. The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail). We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. You can see what analysts are predicting for Ryman Healthcare in this interactive graph of future profit estimates. We'd be remiss not to mention the difference between Ryman Healthcare's total shareholder return (TSR) and its share price return. The TSR attempts to capture the value of dividends (as if they were reinvested) as well as any spin-offs or discounted capital raisings offered to shareholders. Ryman Healthcare's TSR of was a loss of 77% for the 5 years. That wasn't as bad as its share price return, because it has paid dividends. While the broader market gained around 8.7% in the last year, Ryman Healthcare shareholders lost 34%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 12% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand Ryman Healthcare better, we need to consider many other factors. Take risks, for example - Ryman Healthcare has 2 warning signs (and 1 which is a bit concerning) we think you should know about. There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on New Zealander exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
PepsiCo (NasdaqGS:PEP) Launches Exclusive Samii Ryan Fashion Collaboration for Summer 2025
PepsiCo recently launched an exclusive capsule collection in partnership with streetwear brand Samii Ryan. Over the past month, PepsiCo's share price rose by 4%, aligning with the generally positive market trend while slightly outperforming the flat movement observed recently. The alliance with Samii Ryan may have provided additional excitement around the company's brand image. The launch of Thirst Guards, a unique beverage delivery initiative, may also have contributed positively. Meanwhile, the appointment of a new CEO for the Australia and New Zealand Foods division is expected to help focus on growth in the region. PepsiCo has 2 weaknesses we think you should know about. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent partnership between PepsiCo and streetwear brand Samii Ryan, along with innovative initiatives like the Thirst Guards, has contributed positively to PepsiCo's brand image and may stimulate consumer engagement. These developments, combined with the new leadership in the Australia and New Zealand Foods division, could enhance focus in the region and contribute to long-term revenue and earnings growth. Analysts forecast a revenue of $99.5 billion and earnings of $12.2 billion by 2028, reflecting a growth trajectory boosted by strategic initiatives such as the Frito Redesign and SAP rollout. Over the last five years, PepsiCo's total return, comprising share price appreciation and dividends, was 16.58%. This is indicative of its steady performance, although it underperformed both the US Market, which returned 13%, and the US Beverage industry, which saw a decline of 3.5%, over the past year. Presently, PepsiCo's shares, trading at US$130.74, suggest a 13.7% upside opportunity compared to the analyst consensus target of US$151.55. This indicates room for appreciation if the forecasted improvements in revenue and margins materialize as expected, positioning PepsiCo close to its fair valuation amidst current market conditions. Upon reviewing our latest valuation report, PepsiCo's share price might be too pessimistic. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:PEP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
